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Abstract
Background: Glycemic control affects cardiovascular risk factors positively. The purpose of 
this study was to assess B-type natriuretic peptide (BNP) levels in patients with poorly con-
trolled diabetes before and after glycemic regulation was achieved.
Methods: The study was performed in a prospective design. The study population consisted 
of 79 consecutive diabetic patients with poor glycemic control. All subjects underwent transtho-
racic echocardiography. Levels of fasting plasma glucose, glycosylated hemoglobin (HbA1c), 
lipid parameters, and BNP were measured before the onset of the treatment and after glycemic 
regulation was achieved.
Results: A significant decrease in BNP (95.0 [4.0–1807] ng/L vs. 52.0 [2.1–987.0] ng/L, p < 
0.001) levels were observed, after improving glycemic control. The decrease in BNP levels was 
positively correlated with the decrease in HbA1c (r = 0.345, p = 0.003) and fasting plasma 
glucose (r = 0.366, p = 0.002). There was no correlation between the decrease in BNP levels 
and lipid parameters (p = NS).
Conclusions: We conclude that poor glycemic control may cause high levels of BNP which may 
lead to overdiagnosis of congestive heart failure. We suggest that HbA1c and fasting plasma 
glucose should be checked in patients with high levels of BNP. (Cardiol J 2014; 21, 3: 252–256)
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Introduction
Glycemic optimization is a crucial part of ma-
nagement in type 2 diabetes. It can be achieved by 
diet, weight loss, oral anti-diabetics and insulin the-
rapy. Improving glycemic control positively affects 
cardiovascular risk factors such as plasma lipids, 
thrombotic markers, and blood pressure [1–4].
B-type natriuretic peptides (BNP) are produ-
ced in ventricular cardiomyocytes, and secreted 
in response to volume expansion or pressure 
overload. The BNP test is widely used to diagnose 
preclinical heart disease or to confirm the cardiac 
etiology in symptomatic patients. BNP can be 
affected by several extra-cardiac conditions such 
as rheumatic diseases, pulmonary diseases [5, 6].
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Although there are several studies evaluating 
the effect of glycemic control on some biochemical 
markers such as lipids in diabetic patients, there is 
a limited number of controversial studies assessing 
the effect of the glycemic control on the BNP levels. 
The aim of this study is to evaluate the relationship 
between the glycemic control and the BNP levels.
Methods
The study was performed in a prospective 
design. The study population consisted of 79 con-
secutive diabetic patients with poor glycemic con-
trol defined as glycosylated hemoglobin (HbA1c) 
≥ 8.5% (69 mmol/mol).
Exclusion criteria were the presence of co-
ronary artery disease, overt heart failure (using 
Framingham criteria), left ventricular systolic dys-
function (ejection fraction < 40%), pregnancy or 
lactation, hepatic or renal dysfunction, significant 
neurological or psychological diseases, inflamma-
tory bowel diseases, and systemic autoimmune 
diseases such as systemic lupus erythematosus, 
rheumatoid arthritis, and scleroderma. Changes 
in antihypertensive and anti-lipidemic drugs were 
exclusion criteria for the study. The study protocol 
is in accordance with the Declaration of Helsinki. 
The Local Ethics Committee approved the study 
protocol. All patients gave their informed consents.
All subjects underwent an initial screening 
assessment that included a medical history and 
physical examination. All subjects were hospitali-
zed for the glycemic regulation. All subjects were 
administered the same type of analogue insulin 
treatment (Novomix®, Novonordisk®) for glyce-
mic regulation. All subjects underwent transtho-
racic echocardiography before and after insulin 
treatment. Fasting plasma glucose, HbA1c, lipid 
parameters, BNP, renal and liver function tests, 
electrolytes, were obtained at baseline and after 
2 weeks of insulin treatment.
Fasting blood samples were obtained by the 
venipuncture of large antecubital veins of the stu-
died patients without stasis, after a 12-h fast. The 
samples were then centrifuged immediately; the 
plasma was separated and stored at –80oC. In order 
to avoid variation, all samples were studied on the 
same day and with the same kit. Total cholesterol 
(Lot No: B540, Konelab) and triglyceride (Lot No: 
C186, Konelab) were measured with enzymatic 
colorimetric tests. Low-density lipoprotein-cho-
lesterol (LDL-C) (Lot No: C435, Konelab) and 
high-density lipoprotein-cholesterol (HDL-C) 
(Lot No: C136, Konelab) were measured with the 
homogeneous enzymatic colorimetric test. HbA1c 
measurements were performed by ion-exchange 
high-performance liquid chromatography with 
Tosoh G7 (Tosoh, Grove City, OH). 
The concentrations of BNP were determi-
ned with a 2-site sandwich chemiluminescence 
immunoassay (Lot No.: 22161145, reference No.: 
02816634) on the ADVIA® Centaur® platform 
(Siemens Healthcare Diagnostic, IL, USA). The 
ADVIA Centaur BNP assay is a fully automated 
2-site sandwich immunoassay using direct chemi-
luminescent technology, which applies constant 
amounts of 2 monoclonal antibodies. The first 
antibody, in the Lite reagent, is acridinium ester 
labeled monoclonal mouse anti-human BNP F(ab’) 
× fragment specific to the ring structure of BNP. 
The second antibody, in the solid phase, is a bio-
tinylated monoclonal mouse anti-human antibody 
specific to the C-terminal portion of BNP, which 
is coupled to streptavidin magnetic particles. The 
limit of detection for this assay was 0.5 ng/L and 
showed that the within-run and total imprecision 
coefficient of variation was 3.5%. Values less than 
0.5 ng/L were regarded as non-detectable.
Transthoracic echocardiography: Transtho- 
racic echocardiography examination was perfor-
med to all subjects by using a System Three (GE 
Vingmed Ultrasound, Horten, Norway) cardiac 
ultrasound scanner and 2.5–3.5 MHz transducers.
Echocardiography of the left ventricle: The 
following parameters were measured from cross-
-sectional echocardiographic images of the left ven-
tricle: 1) end-diastolic and end-systolic diameter 
[cm]; 2) fractional shortening (FS %); 3) ejection 
fraction (EF %).
Doppler echocardiography: Flow velocity 
indexes were obtained using pulsed and continuous 
wave Doppler from apical projections, and measu-
rements were made utilizing the software of the 
ultrasound equipment. Mitral diastolic flow was ob-
tained after the pulsed Doppler sample volume was 
positioned perpendicularly to the tips of the mitral 
valve leaflets. The Doppler cursor was then moved 
towards the left ventricular outflow position, and 
the sample volume was placed approximately 1 cm 
proximally to the aortic valve so that it would come 
in contact with the anterior mitral valve leaflet. 
Isovolumic relaxation time [ms] was measured as 
the interval between the end of the aortic click 
artifact and the onset of mitral inflow waveform.
The following indexes were measured from 
the mitral and tricuspid valve diastolic wave form: 
peak early (E) and atrial (A) flow velocities [m/s], 
E/A ratio of the left ventricular diastolic filling. 
Heart rate [bpm] was measured from simultaneous 
electrocardiogram recordings.
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Pulsed Doppler tissue echocardiography: 
The myocardial velocities of the left ventricle were 
measured sampling the mitral annulus excursion 
at lateral sites in the 4-chamber view. Care was 
taken to keep the ultrasound beam perpendicular 
to the plane of the annulus in order to minimize 
the angle between the beam and the direction of 
annular motion. The width of the sample volume 
was 3–5 mm. Measurements were focused on the 
systolic myocardial wave (S’), the early-diastolic 
(E’) and end-diastolic myocardial (A’) waves. Usual-
ly, several cardiac cycles were acquired and the best 
2 consecutive ones were analyzed and averaged.
Statistical methods
Distribution of the continuous variables was 
determined by the Kolmogorov-Smirnov test. 
Continuous variables with normal distribution 
were expressed as mean ± SD, variables with 
skew distribution are expressed as median (mi-
nimum–maximum), and categorical variables are 
expressed as percentages. The paired sample t-test 
was used for normally distributed variables and 
the Wilcoxon rank-sum test for skew distributed 
variables. Pearson and Spearman analysis was used 
to identify correlations between study parameters. 
For all statistics, a 2-sided p value < 0.05 was con-
sidered statistically significant. All analyses were 
performed with SPSS 10.0 for Windows.
Results
A total of 79 diabetic patients with poor gly-
cemic control were examined. Demographic data, 
clinical characteristics, and medications are shown 
in Table 1. The mean age was 60.3 ± 11.3 years. 
The majority of patients were female (53; 67%). 
Mean duration of diabetes was 7.5 ± 3.5 years. 
Systolic blood pressure and diastolic blood pres-
sure were significantly decreased after improving 
glycemic control. There was no significant change 
in heart rate.
All subjects had normal ejection fraction. The 
transthoracic echocardiographic parameters of 
subjects are presented in Table 2. No significant 
difference was found in conventional Doppler and 
pulsed wave tissue Doppler parameters before and 
after glycemic control. There was no association 
between the measured echocardiographic indexes 
and BNP levels.
Biochemical parameters before and after 
glycemic control are presented in Table 3. Fasting 
plasma glucose levels (306.3 ± 119.4 mg/dL vs. 
122.5 ± 35.0 mg/dL, p < 0.001), HbA1c levels 
Table 1. Demographic characteristic and medi-
cations of subjects.
Characteristic Patients (n = 79) 
Age [years] 60.3 ± 11.3
Female/Male 53/26 (67/33%)
Hypertension 54 (68%)
Medications and treatments:
Sulfonylurea 18 (23%)
Metformin 52 (66%)
Thiazolidinediones 21 (27%)
Dipeptidyl peptidase-4  
inhibitors
20 (25%)
Table 2. Conventional and tissue Doppler parameters of subjects before and after glycemic control.
Baseline 2 weeks of glycemic control P
Left ventricular end-diastolic diameter [cm] 4.6 ± 0.7 4.5 ± 0.6 NS
Left ventricular end-systolic diameter [cm] 3.1 ± 0.3 3.0 ± 0.2 NS
Left ventricular ejection fraction [%] 66.3 ± 4.7 64.3 ± 5.1 NS
Left ventricular septal wall thickness [cm] 1.1 ± 0.2 1.1 ± 0.2 NS
Left ventricular posterior wall thickness [cm] 1.0 ± 0.1 1.0 ± 0.1 NS
E peak [m/s] 0.72 ± 0.11 0.76 ± 0.13 NS
A peak [m/s] 0.37 ± 0.18 0.41 ± 0.23 NS
E deceleration time [ms] 209.1 ± 31.4 205.4 ± 28.1 NS
Isovolumic relaxation time [ms] 91.3 ± 12.8 89.9 ± 11.4 NS
Mitral early diastolic annular velocity  
of lateral wall (E’) [cm/s]
12.6 ± 2.5 13.1 ± 3.2 NS
Mitral late diastolic annular velocity  
of lateral wall (A’) [cm/s]
9.1 ± 2.1 8.4 ± 2.7 NS
Mitral peak systolic annular velocity  
of lateral wall (S’) [cm/s]
12.5 ± 2.7 11.7 ± 2.6 NS
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(12.1 ± 2.7% [109 ± 6 mmol/mol] vs. 11.0 ± 2.5% 
[86 ± 4 mmol/mol], p < 0.001), total cholesterol 
(227.2 ± 47.3 mg/dL vs. 207.2 ± 45.2 mg/dL, 
p < 0.001), LDL-C (151.3 ± 34.3 mg/dL vs. 139.8 ± 
± 27.8 mg/dL, p < 0.001), triglyceride (199.5 ± 
± 118.4 mg/dL vs. 168.7 ± 92.2 mg/dL, p < 0.001) 
levels were significantly decreased, after improving 
glycemic control. There was no significant change in 
HDL-C (42.7 ± 13.7 mg/dL vs. 42.2 ± 14.8 mg/dL, 
p = NS) levels.
A significant decrease in BNP (95.0 [4.0–1807] 
ng/L vs. 52.0 [2.1–987.0] ng/L, p< 0.001) levels 
was observed after improving glycemic control. 
Distribution of BNP levels before and after treat-
ment is shown in Figure 1. The decrease in BNP 
levels was positively correlated with the decrease 
in HbA1c (r = 0.345, p = 0.003) and fasting plasma 
glucose (r = 0.366, p = 0.002). There was no cor-
relation between decrease in BNP levels and lipid 
parameters and blood pressure (p = NS).
Discussion
In this study, after glycemic control was achie-
ved, significant decrease in BNP and lipid levels 
was observed. To the best of our knowledge, this 
is the first clinical study demonstrating the effect 
of glycemic control on BNP measurements.
In the previous studies, glycemic control 
affects lipids positively [3, 4]. Sánchez-Quesada 
et al. [1] reported that optimizing glycemic con-
trol in patients with type 2 diabetes promotes 
atheroprotective changes, including larger LDL 
size, decreased electronegative LDL, and a higher 
proportion of Lp-PLA2 activity in HDL. Wägner et 
al. [2] demonstrated that improvement of glycemic 
control in type 2 diabetes improves most of the 
components of diabetic dyslipidemia, including 
a shift towards larger LDL particles in subjects 
with phenotype B.
Chronic heart failure (CHF) has been shown 
to be related to diabetes mellitus (DM). Diabetics 
have an increased risk of developing heart failure 
[7], and CHF is an independent risk factor for 
the development of DM [8, 9]. Cardiac functions 
are also associated with impairment of glucose 
metabolism [10]. The mechanisms underlying the 
relation between DM and CHF have not been fully 
elucidated.
Figure 1. Distribution of B-type natriuretic peptide (BNP) 
levels before and after glycemic control; BNP (BT) — 
BNP levels before treatment; BNP (AT) — BNP levels 
after treatment.
Table 3. Biochemical and clinical parameters before and after glycemic control.
Baseline 2 weeks of glycemic control P
Systolic blood pressure [mm Hg] 128.2 ± 9.8 122.0 ± 2.5 < 0.001
Diastolic blood pressure [mm Hg] 82.0 ± 7.8 77.0 ± 2.5 < 0.001
Heart rate [bpm] 72.6 ± 10.4 72.8 ± 11.2 NS
Fasting plasma glucose [mg/dL] 306.3 ± 119.4 122.5 ± 35.0 <0.001
Triglyceride [mg/dL] 199.5 ± 118.4 168.7 ± 92.2 < 0.001
Total cholesterol [mg/dL] 227.2 ± 47.3 207.2 ± 45.2 < 0.001
Low density lipoprotein-cholesterol [mg/dL] 151.3 ± 34.3 139.8 ± 27.8 < 0.001
High density lipoprotein-cholesterol [mg/dL] 42.7 ± 13.7 42.2 ± 14.8 NS
Gama glutamyl transferase [U/L] 32.3 ± 22.0 28.4 ± 13.0 NS
Alanine aminotranferease [U/L] 21.7 ± 8.5 22.6 ± 9.7 NS
Aspartate aminotransferase [U/L] 22.2 ± 7.6 21.6 ± 9.9 NS
Creatinine [mg/dL] 0.97 ± 0.42 0.96 ± 0.48 NS
Glycosylated hemoglobin [%] 12.1 ± 2.7 (109 ± 6) 11.0 ± 2.5 (86 ± 4) < 0.001
0
BNP (BT) BNP (AT)
200
400
600
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There are very few studies investigating the 
effect of hyperglycemia on BNP levels. In an experi-
mental study, after 2 and 4 months of diabetes db/db 
mice developed changes indicative of cardiac failure, 
and their myocardium showed increased mRNA 
expression of atrial and BNPs [11]. Treatment with 
macitentan (dual endothelin receptor antagonist) 
prevented from such abnormalities. Ortola et al. 
[12] found elevated atrial natriuretic peptide (ANP) 
concentrations in diabetic rats and they observed 
reduced glomerular filtration rate after infusion of 
ANP in diabetic rats. They concluded that elevated 
endogenous ANP levels contribute to the hyperfil-
tration observed in early diabetes in the rats [12].
Ciftel et al. [13], investigated the NT-proBNP 
levels in DM and control groups. They found signi-
ficantly higher NT-proBNP levels in the diabetics 
with left ventricular diastolic dysfunction (LVDD) 
than the diabetics without LVDD, and normal con-
trols. The mean NT-proBNP levels in the diabetics 
without LVDD were higher (albeit not significant) 
than in the control group. In another study with 
type 1 DM, glucose infusion caused elevation of 
ANP, but not BNP levels. They also showed in 
another study that plasma concentrations of ANP 
and BNP were elevated in patients with type 1 DM 
[14, 15]. Similarly to our study, they also found 
that plasma BNP concentrations were related to 
HbA1c. The same group has also demonstrated 
that BNP infusion can induce microalbuminuria in 
type 1 DM. In another study, BNP was found to be 
related to HbA1c and QUICKI insulin sensitivity 
index in CHF patients [3].
The reason of the relation between BNP and 
hyperglycemia is not obvious. Hyperglycemia may 
be inducing dysfunction of the cardiac myocytes, 
and/or plasma glucose per se, may be inducing the 
secretion of cardiac natriuretic peptides. Endo-
plasmic reticulum stress associated with DM leads 
to cardiac myocyte apoptosis and cardiomyopathy as 
well [16, 17]. Endoplasmic reticulum stress may be 
the link between elevated BNP secretion and DM.
Conclusions
We demonstrated a significant decrease in 
BNP and lipid levels by achieving glycemic con-
trol. This finding emphasizes the importance of 
glycemic control in diabetic patients. Poor glycemic 
control may cause high BNP measurements which 
can lead to overdiagnosis of CHF. We suggest that 
HbA1c and fasting plasma glucose should be che-
cked in diabetic patients with high levels of BNP.
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